DermatologyNovartis
Novartis Reports Positive Phase 3 Results for Remibrutinib in Chronic Spontaneous Urticaria
BMI
Biotechnology Media Insights
Editorial Team · June 22, 2025
Novartis announces positive Phase 3 REMIX-1 and REMIX-2 trial results showing remibrutinib significantly reduces urticaria symptoms in patients uncontrolled on antihistamines.
Novartis today announced positive results from the Phase 3 REMIX-1 and REMIX-2 trials evaluating remibrutinib in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment. Both trials met their primary endpoints, demonstrating significant reductions in the Urticaria Activity Score over 7 days (UAS7) compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.